Which drug class has mortality benefit in HFrEF in addition to ACE inhibitors, ARBs, and beta-blockers?

Which drug class has mortality benefit in HFrEF in addition to ACE inhibitors, ARBs, and beta-blockers?

• A. Aldosterone antagonists
• B. Loop diuretics
• C. Nitrates
• D. Calcium channel blockers

Answer: (A)

Aldosterone antagonists extend survival when added to standard therapy for heart failure with reduced ejection fraction because they block the harmful effects of aldosterone on the heart and vessels. Aldosterone promotes sodium and water retention, potassium loss, and promotes myocardial and vascular fibrosis and remodeling. By blocking this receptor, spironolactone and eplerenone reduce these adverse processes, which translates into lower mortality and fewer hospitalizations beyond ACE inhibitors, ARBs, and beta-blockers. This benefit is well supported by large trials. Spironolactone reduced all-cause mortality in patients with severe HF already on standard therapy. Eplerenone, started after myocardial infarction in patients with left ventricular dysfunction, also lowered cardiovascular and all-cause mortality. Because these drugs can raise potassium and affect kidney function, it’s important to monitor potassium and creatinine soon after starting or changing the dose and periodically thereafter, and to avoid use if potassium is high or kidney function is poor. Other classes mainly address symptoms or have limited mortality data in this combined therapy context; there is a specific population where hydralazine–nitrate shows mortality benefit, but in the general case of adding to ACE inhibitors, ARBs, and beta-blockers, the aldosterone antagonists are the proven option for mortality benefit.

Aldosterone antagonists extend survival when added to standard therapy for heart failure with reduced ejection fraction because they block the harmful effects of aldosterone on the heart and vessels. Aldosterone promotes sodium and water retention, potassium loss, and promotes myocardial and vascular fibrosis and remodeling. By blocking this receptor, spironolactone and eplerenone reduce these adverse processes, which translates into lower mortality and fewer hospitalizations beyond ACE inhibitors, ARBs, and beta-blockers.

This benefit is well supported by large trials. Spironolactone reduced all-cause mortality in patients with severe HF already on standard therapy. Eplerenone, started after myocardial infarction in patients with left ventricular dysfunction, also lowered cardiovascular and all-cause mortality. Because these drugs can raise potassium and affect kidney function, it’s important to monitor potassium and creatinine soon after starting or changing the dose and periodically thereafter, and to avoid use if potassium is high or kidney function is poor.

Other classes mainly address symptoms or have limited mortality data in this combined therapy context; there is a specific population where hydralazine–nitrate shows mortality benefit, but in the general case of adding to ACE inhibitors, ARBs, and beta-blockers, the aldosterone antagonists are the proven option for mortality benefit.